Minocycline in Patients With Alzheimer's Disease

Completed · Phase 2

Conditions studied: Mild Cognitive Impairment, Alzheimer's Disease

In brief

Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.

Key facts

Study ID
NCT01463384
Run by
Huntington Medical Research Institutes
People needed
13
Starts
2011-09-01
Expected to finish
2012-10-01
Last updated by the study team
2014-09-25

Who can join

Age: 55 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.